Nov. 1 at 4:28 PM
Okay, this may be comparing apples to oranges, but perhaps not. It is at least kind of interesting I think.
Left is
$AVXL's placebo controled study data for *early* AD patients, and right is
$SAVA's open-label going into randomized withdrawal study with the blue lines being for *mild* AD patients.
Note in the
$AVXL trial at 24 weeks their is just a small amount of separation between drug & placebo, but a much larger one at 48 weeks. The RW part for
$SAVA only went on for six months (so just a bit longer than 24 weeks), and we see the small separation between drug & placebo at that point. Perhaps
$SAVA should've run their RW for at least a year? Would've have that data by now. But also may be good news for
$SAVA that a
$AVAL's placebo study looks kind-of like it over same time period?
